| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANA.410370305 |
| P698 | PubMed publication ID | 7695229 |
| P2093 | author name string | Iwatsubo T | |
| Suzuki N | |||
| Ihara Y | |||
| Mann DM | |||
| Odaka A | |||
| P433 | issue | 3 | |
| P921 | main subject | Down syndrome | Q47715 |
| P304 | page(s) | 294-299 | |
| P577 | publication date | 1995-03-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome | |
| P478 | volume | 37 |
| Q48865847 | A beta40 is a major form of beta-amyloid in nonhuman primates |
| Q37331417 | A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain |
| Q26798983 | A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome |
| Q31041418 | A new structural model of Alzheimer's Aβ42 fibrils based on electron paramagnetic resonance data and Rosetta modeling |
| Q55021292 | A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects. |
| Q48458709 | A unifying hypothesis of Alzheimer's disease. III. Risk factors |
| Q48361836 | Abeta-42 deposition precedes other changes in PS-1 Alzheimer's disease |
| Q48799582 | Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. |
| Q34928142 | Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. |
| Q36983588 | Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. |
| Q48482752 | Abeta42, presenilins, and Alzheimer's disease |
| Q44021050 | Abeta42-peptide assembly on lipid bilayers |
| Q48601563 | Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins |
| Q28366524 | Accumulation of amyloid beta-protein in the low-density membrane domain accurately reflects the extent of beta-amyloid deposition in the brain |
| Q28513133 | Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein |
| Q37102001 | Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology |
| Q22251265 | Alzheimer disease and Down syndrome: factors in pathogenesis |
| Q37028176 | Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils |
| Q35102897 | Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet |
| Q48223080 | Ameliorative effects of a neuroprotective agent, T-817MA, on place learning deficits induced by continuous infusion of amyloid-beta peptide (1-40) in rats |
| Q59099374 | Amyloid and presenilins in the pathobiology of Alzheimer’s disease |
| Q42980695 | Amyloid beta 1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs. |
| Q35773873 | Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques |
| Q74477367 | Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease |
| Q48617231 | Amyloid beta-protein (Abeta) 1-40 but not Abeta1-42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain |
| Q41495946 | Amyloid precursor protein, copper and Alzheimer's disease |
| Q34175164 | Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption |
| Q39507612 | Amyloid-beta-protein isoforms in brain of subjects with PS1-linked, beta APP-linked and sporadic Alzheimer disease |
| Q34080692 | Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease |
| Q35754595 | Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging |
| Q35764562 | Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain |
| Q31804341 | Beta-amyloid (1-42) affects MTT reduction in astrocytes: implications for vesicular trafficking and cell functionality |
| Q38166669 | Biomarker modelling of early molecular changes in Alzheimer's disease |
| Q40912777 | C terminus of presenilin is required for overproduction of amyloidogenic Abeta42 through stabilization and endoproteolysis of presenilin |
| Q58614421 | CSF sTREM2 in delirium-relation to Alzheimer's disease CSF biomarkers Aβ42, t-tau and p-tau |
| Q41144848 | Catastrophe, chaos and Alzheimer's disease. The F E Williams Lecture |
| Q57306417 | Chapter 3 Structural Changes in the Aged Brain |
| Q48339041 | Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome |
| Q48643481 | Characterization of amyloid beta protein species in cerebral amyloid angiopathy of a squirrel monkey by immunocytochemistry and enzyme-linked immunosorbent assay |
| Q36438065 | Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid beta peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiop |
| Q47577090 | Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice |
| Q30361851 | Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease. |
| Q28216994 | Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric |
| Q26777254 | Dissecting Alzheimer disease in Down syndrome using mouse models |
| Q48211250 | Distal Amyloid β-Protein Fragments Template Amyloid Assembly. |
| Q33942884 | Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease |
| Q53346702 | Distinguishable effects of presenilin-1 and APP717 mutations on amyloid plaque deposition. |
| Q48183391 | Distribution and fluidizing action of soluble and aggregated amyloid beta-peptide in rat synaptic plasma membranes |
| Q48102481 | Down syndrome, beta-amyloid and neuroimaging |
| Q40950151 | Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein |
| Q52138111 | Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. |
| Q53201642 | Evidence that Aβ42 is the real culprit in alzheimer's disease |
| Q36689365 | Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities |
| Q34063772 | Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo |
| Q35782745 | Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. |
| Q46656379 | Gel electrophoretic distinction between Congo Red nonreactive beta-amyloid (1-42) and beta-amyloid (1-40). |
| Q33747695 | Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies |
| Q46330873 | Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology |
| Q33795144 | Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells |
| Q48682997 | Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains |
| Q36495294 | Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. |
| Q37407381 | In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model. |
| Q28118975 | Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1 |
| Q74313854 | Increased plasma amyloid beta protein 1-42 levels in Down syndrome |
| Q24317439 | Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease |
| Q22001054 | Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. |
| Q26745369 | Intracerebral haemorrhage in Down syndrome: protected or predisposed? |
| Q82010316 | Intracerebral hemorrhage |
| Q48262430 | Is there a genetic basis for the deposition of beta-amyloid after fatal head injury? |
| Q33245678 | Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. |
| Q55443889 | Metabolic and Vascular Imaging Biomarkers in Down Syndrome Provide Unique Insights Into Brain Aging and Alzheimer Disease Pathogenesis. |
| Q64270312 | Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer's Disease |
| Q70898846 | Microglial cells and amyloid beta protein (A beta) deposition; association with A beta 40-containing plaques |
| Q24292312 | Molecular cloning and characterization of CALP/KChIP4, a novel EF-hand protein interacting with presenilin 2 and voltage-gated potassium channel subunit Kv4 |
| Q38464322 | Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer disease, and effect of postmortem tissue archival on TUNEL. |
| Q24297568 | Mostly separate distributions of CLAC- versus Abeta40- or thioflavin S-reactivities in senile plaques reveal two distinct subpopulations of beta-amyloid deposits |
| Q46830566 | Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome. |
| Q53210802 | Neuropathology in the Down's syndrome brain. |
| Q42369878 | Non-aggregated Aβ25-35 Upregulates Primary Astrocyte Proliferation In Vitro |
| Q48312541 | Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE |
| Q34838288 | Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer's disease |
| Q42215600 | On the nucleation of amyloid beta-protein monomer folding |
| Q60721200 | Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease |
| Q37625928 | Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment |
| Q51914558 | Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. |
| Q34292024 | Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study |
| Q73417757 | Plasma amyloid beta protein 1-42 levels are increased in old Down Syndrome but not in young Down Syndrome |
| Q35773537 | Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene |
| Q53325111 | Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. |
| Q35787262 | Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation |
| Q70908071 | Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome |
| Q30497860 | Presenilin-2 mutation causes early amyloid accumulation and memory impairment in a transgenic mouse model of Alzheimer's disease |
| Q33835683 | Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms |
| Q33760959 | Progress toward valid transgenic mouse models for Alzheimer's disease |
| Q90275269 | Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier - phenotypic variability in autosomal dominant Alzheimer's disease |
| Q35745836 | Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. |
| Q47837479 | Pulsatile stretch as a novel modulator of amyloid precursor protein processing and associated inflammatory markers in human cerebral endothelial cells |
| Q35765178 | Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. |
| Q53237800 | Quantitation of amyloid-beta peptides in biological milieu using a novel homogeneous time-resolved fluorescence (HTRF) assay. |
| Q36767282 | Quantitative proteomic analysis of amniocytes reveals potentially dysregulated molecular networks in Down syndrome. |
| Q41615924 | Reactive oxygen species and Alzheimer's disease. |
| Q52030675 | Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of beta-amyloid (1-40). |
| Q35118684 | Relation between insulin, insulin-related factors, and plasma amyloid beta peptide levels at midlife in a population-based study |
| Q33968271 | S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors |
| Q29614374 | Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease |
| Q35774013 | Selective binding of soluble Abeta1-40 and Abeta1-42 to a subset of senile plaques |
| Q46529505 | Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease |
| Q42796058 | The AMY antigen co-occurs with abeta and follows its deposition in the amyloid plaques of Alzheimer's disease and down syndrome |
| Q48911162 | The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology |
| Q55455361 | The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer's disease in individuals with Down syndrome. |
| Q35599843 | The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. |
| Q36806654 | The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects |
| Q40795556 | The first proline of PALP motif at the C terminus of presenilins is obligatory for stabilization, complex formation, and gamma-secretase activities of presenilins |
| Q40619489 | The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol |
| Q34409316 | The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease |
| Q33867210 | The mouse model of Down syndrome Ts65Dn presents visual deficits as assessed by pattern visual evoked potentials |
| Q46244313 | The past, present, and future of disease-modifying therapies for Alzheimer's disease. |
| Q39951771 | The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity |
| Q36799963 | The relationship between cerebral amyloid angiopathy and cortical microinfarcts in brain ageing and Alzheimer's disease. |
| Q42463004 | The role of A beta 42 in Alzheimer's disease |
| Q37067641 | The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia |
| Q38015346 | Therapeutic interventions targeting Beta amyloid pathogenesis in an aging dog model |
| Q36248545 | Toxicity in rat primary neurons through the cellular oxidative stress induced by the turn formation at positions 22 and 23 of Aβ42. |
| Q33557364 | Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle |
| Q38865260 | Variable deposition of amyloid beta-protein (A beta) with the carboxy-terminus that ends at residue valine40 (A beta 40) in the cerebral cortex of patients with Alzheimer's disease: a double-labeling immunohistochemical study with antibodies specifi |
| Q28301724 | What is the dominant Abeta species in human brain tissue? A review |
| Q48770369 | beta-Amyloid (A beta) deposition in the brains of aged orangutans |
| Q59329055 | miR-15b reduces amyloid-β accumulation in SH-SY5Y cell line through targetting NF-κB signaling and BACE1 |
Search more.